Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jul;34(1):11–20. doi: 10.1111/j.1365-2125.1992.tb04101.x

Medical management of hypercalcaemia.

S H Ralston 1
PMCID: PMC1381369  PMID: 1633063

Abstract

1. Hypercalcaemia is a common disorder, which frequently requires specific treatment either to control symptoms, or to prevent the development of irreversible organ damage or death. Although the best and most effective way of controlling hypercalcaemia in the long-term is to treat the underlying cause, medical antihypercalcaemic therapy is often required in clinical practice, either as a holding measure, or because the primary disease cannot itself be treated. 2. The mainstays of medical antihypercalcaemic therapy are firstly, to promote calcium excretion by the kidney by restoring extracellular volume with intravenous saline and secondly, to administer pharmacological agents which inhibit bone resorption. Measures which seek to reduce intestinal calcium absorption are seldom effective. 3. Intravenous bisphosphonates are the treatment of first choice for the initial management of hypercalcaemia, followed by continued oral, or repeated intravenous bisphosphonates to prevent relapse. These drugs have a relatively slow onset of action (1-3 days) but have potent and sustained inhibitory effects on bone resorption, resulting in a long duration of action (12-30 days). 4. Of the other agents available, calcitonin has an important place in the management of severe hypercalcaemia where a rapid effect is desirable; calcitonin is best used in conjunction with a bisphosphonate however, because of its short duration of action. Intravenous phosphate also has a place in the emergency management of severe hypercalcaemia, but is probably best reserved for patients in whom other less toxic therapies have failed. Corticosteroids are generally ineffective except in certain specific instances and are best avoided in the routine treatment of undiagnosed hypercalcaemia.

Full text

PDF
11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDERSON J., HARPER C., DENT C. E., PHILPOT G. R. Effect of cortisone on calcium metabolism in sarcoidosis with hypercalcaemia; possibly antagonistic actions of cortisone and vitamin D. Lancet. 1954 Oct 9;267(6841):720–724. doi: 10.1016/s0140-6736(54)90492-4. [DOI] [PubMed] [Google Scholar]
  2. Adami S., Bolzicco G. P., Rizzo A., Salvagno G., Bertoldo F., Rossini M., Suppi R., Lo Cascio V. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner. 1987 Aug;2(5):395–404. [PubMed] [Google Scholar]
  3. Agus Z. S., Gardner L. B., Beck L. H., Goldberg M. Effects of parathyroid hormone on renal tubular reabsorption of calcium, sodium, and phosphate. Am J Physiol. 1973 May;224(5):1143–1148. doi: 10.1152/ajplegacy.1973.224.5.1143. [DOI] [PubMed] [Google Scholar]
  4. Benabe J. E., Martinez-Maldonado M. Hypercalcemic nephropathy. Arch Intern Med. 1978 May;138(5):777–779. [PubMed] [Google Scholar]
  5. Bijvoet O. L., van der Sluys Veer J., de Vries H. R., van Koppen A. T. Natriuretic effect of calcitonin in man. N Engl J Med. 1971 Apr 1;284(13):681–688. doi: 10.1056/NEJM197104012841301. [DOI] [PubMed] [Google Scholar]
  6. Binstock M. L., Mundy G. R. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 1980 Aug;93(2):269–272. doi: 10.7326/0003-4819-93-2-269. [DOI] [PubMed] [Google Scholar]
  7. Body J. J., Borkowski A., Cleeren A., Bijvoet O. L. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol. 1986 Aug;4(8):1177–1183. doi: 10.1200/JCO.1986.4.8.1177. [DOI] [PubMed] [Google Scholar]
  8. Body J. J., Pot M., Borkowski A., Sculier J. P., Klastersky J. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. Am J Med. 1987 May;82(5):957–963. doi: 10.1016/0002-9343(87)90158-6. [DOI] [PubMed] [Google Scholar]
  9. Bonjour J. P., Philippe J., Guelpa G., Bisetti A., Rizzoli R., Jung A., Rosini S., Kanis J. A. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone. 1988;9(3):123–130. doi: 10.1016/8756-3282(88)90001-4. [DOI] [PubMed] [Google Scholar]
  10. Bounameaux H. M., Schifferli J., Montani J. P., Jung A., Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet. 1983 Feb 26;1(8322):471–471. doi: 10.1016/s0140-6736(83)91465-4. [DOI] [PubMed] [Google Scholar]
  11. Boyce B. F., Smith L., Fogelman I., Johnston E., Ralston S., Boyle I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984 Apr 14;1(8381):821–824. doi: 10.1016/s0140-6736(84)92272-4. [DOI] [PubMed] [Google Scholar]
  12. Brenner D. E., Harvey H. A., Lipton A., Demers L. A study of prostaglandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy. Cancer. 1982 Feb 1;49(3):556–561. doi: 10.1002/1097-0142(19820201)49:3<556::aid-cncr2820490327>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  13. Breuer R. I., LeBauer J. Caution in the use of phosphates in the treatment of severe hypercalcemia. J Clin Endocrinol Metab. 1967 May;27(5):695–698. doi: 10.1210/jcem-27-5-695. [DOI] [PubMed] [Google Scholar]
  14. Brown R. C., Aston J. P., Weeks I., Woodhead J. S. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 1987 Sep;65(3):407–414. doi: 10.1210/jcem-65-3-407. [DOI] [PubMed] [Google Scholar]
  15. Cantwell B. M., Harris A. L. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed) 1987 Feb 21;294(6570):467–469. doi: 10.1136/bmj.294.6570.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Carey R. W., Schmitt G. W., Kopald H. H., Kantrowitz P. A. Massive extraskeletal calcification during phosphate treatment of hypercalcemia. Arch Intern Med. 1968 Aug;122(2):150–155. [PubMed] [Google Scholar]
  17. Chambers T. J. The pathobiology of the osteoclast. J Clin Pathol. 1985 Mar;38(3):241–252. doi: 10.1136/jcp.38.3.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Chapuy M. C., Meunier P. J., Alexandre C. M., Vignon E. P. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest. 1980 May;65(5):1243–1247. doi: 10.1172/JCI109780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Coleman R. E., Rubens R. D. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer. 1987 Oct;56(4):465–469. doi: 10.1038/bjc.1987.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Davies M., Mawer E. B., Hayes M. E., Lumb G. A. Abnormal vitamin D metabolism in Hodgkin's lymphoma. Lancet. 1985 May 25;1(8439):1186–1188. doi: 10.1016/s0140-6736(85)92864-8. [DOI] [PubMed] [Google Scholar]
  21. Davis J. R., Heath D. A. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Br J Clin Pharmacol. 1989 Sep;28(3):269–274. doi: 10.1111/j.1365-2125.1989.tb05426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Douglas D. L., Duckworth T., Russell R. G., Kanis J. A., Preston C. J., Preston F. E., Prenton M. A., Woodhead J. S. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980 May 17;1(8177):1043–1047. doi: 10.1016/s0140-6736(80)91496-8. [DOI] [PubMed] [Google Scholar]
  23. Evans R. A. Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism. Aust N Z J Med. 1987 Feb;17(1):58–59. doi: 10.1111/j.1445-5994.1987.tb05052.x. [DOI] [PubMed] [Google Scholar]
  24. FITZ T. E., HALLMAN B. L. Mental changes associated with hyperparathyroidism; report of two cases. AMA Arch Intern Med. 1952 Apr;89(4):547–551. doi: 10.1001/archinte.1952.00240040026003. [DOI] [PubMed] [Google Scholar]
  25. Fisken R. A., Heath D. A., Bold A. M. Hypercalcaemia--a hospital survey. Q J Med. 1980 Autumn;49(196):405–418. [PubMed] [Google Scholar]
  26. Gallacher S. J., Ralston S. H., Patel U., Boyle I. T. Side-effects of pamidronate. Lancet. 1989 Jul 1;2(8653):42–43. doi: 10.1016/s0140-6736(89)90277-8. [DOI] [PubMed] [Google Scholar]
  27. Gibbs C. J., Peacock M. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Postgrad Med J. 1986 Oct;62(732):937–938. doi: 10.1136/pgmj.62.732.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Goldsmith R. S., Ingbar S. H. Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med. 1966 Jan 6;274(1):1–7. doi: 10.1056/NEJM196601062740101. [DOI] [PubMed] [Google Scholar]
  29. Gurney H., Kefford R., Stuart-Harris R. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Lancet. 1989 Jul 29;2(8657):241–244. doi: 10.1016/s0140-6736(89)90429-7. [DOI] [PubMed] [Google Scholar]
  30. Hamdy N. A., Gray R. E., McCloskey E., Galloway J., Rattenbury J. M., Brown C. B., Kanis J. A. Clodronate in the medical management of hyperparathyroidism. Bone. 1987;8 (Suppl 1):S69–S77. [PubMed] [Google Scholar]
  31. Harinck H. I., Bijvoet O. L., Plantingh A. S., Body J. J., Elte J. W., Sleeboom H. P., Wildiers J., Neijt J. P. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med. 1987 Jun;82(6):1133–1142. doi: 10.1016/0002-9343(87)90215-4. [DOI] [PubMed] [Google Scholar]
  32. Harinck H. I., Papapoulos S. E., Blanksma H. J., Moolenaar A. J., Vermeij P., Bijvoet O. L. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 1987 Nov 21;295(6609):1301–1305. doi: 10.1136/bmj.295.6609.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Harrison M., James N., Broadley K., Bloom S. R., Armour R., Wimalawansa S., Heath D., Waxman J. Somatostatin analogue treatment for malignant hypercalcaemia. BMJ. 1990 May 19;300(6735):1313–1314. doi: 10.1136/bmj.300.6735.1313-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hasling C., Charles P., Mosekilde L. Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med. 1987 Feb 23;82(2A):51–54. doi: 10.1016/0002-9343(87)90487-6. [DOI] [PubMed] [Google Scholar]
  35. Hebert L. A., Lemann J., Jr, Petersen J. R., Lennon E. J. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest. 1966 Dec;45(12):1886–1894. doi: 10.1172/JCI105493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Heller S. R., Hosking D. J. Renal handling of calcium and sodium in metastatic and non-metastatic malignancy. Br Med J (Clin Res Ed) 1986 Mar 1;292(6520):583–586. doi: 10.1136/bmj.292.6520.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Horiuchi N., Caulfield M. P., Fisher J. E., Goldman M. E., McKee R. L., Reagan J. E., Levy J. J., Nutt R. F., Rodan S. B., Schofield T. L. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science. 1987 Dec 11;238(4833):1566–1568. doi: 10.1126/science.3685994. [DOI] [PubMed] [Google Scholar]
  38. Hosking D. J., Cowley A., Bucknall C. A. Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981 Autumn;50(200):473–481. [PubMed] [Google Scholar]
  39. Hosking D. J., Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med. 1984 Summer;53(211):359–368. [PubMed] [Google Scholar]
  40. Iqbal S. J., Giles M., Ledger S., Nanji N., Howl T. Need for albumin adjustments of urgent total serum calcium. Lancet. 1988 Dec 24;2(8626-8627):1477–1478. doi: 10.1016/s0140-6736(88)90945-2. [DOI] [PubMed] [Google Scholar]
  41. Jacobs T. P., Gordon A. C., Silverberg S. J., Shane E., Reich L., Clemens T. L., Gundberg C. M. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. Am J Med. 1987 Feb 23;82(2A):42–50. doi: 10.1016/0002-9343(87)90486-4. [DOI] [PubMed] [Google Scholar]
  42. Jacobs T. P., Siris E. S., Bilezikian J. P., Baquiran D. C., Shane E., Canfield R. E. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med. 1981 Mar;94(3):312–316. doi: 10.7326/0003-4819-94-3-312. [DOI] [PubMed] [Google Scholar]
  43. Jones P. B., McCloskey E. V., Kanis J. A. Transient taste-loss during treatment with etidronate. Lancet. 1987 Sep 12;2(8559):637–637. doi: 10.1016/s0140-6736(87)93036-4. [DOI] [PubMed] [Google Scholar]
  44. Judson I., Booth F., Gore M., McElwain T. Chronic high-dose pamidronate in refractory malignant hypercalcaemia. Lancet. 1990 Mar 31;335(8692):802–802. doi: 10.1016/0140-6736(90)90926-v. [DOI] [PubMed] [Google Scholar]
  45. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med. 1982 Feb;72(2):221–226. doi: 10.1016/0002-9343(82)90813-0. [DOI] [PubMed] [Google Scholar]
  46. Kanis J. A., McCloskey E. V., Paterson A. H. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet. 1990 Jan 20;335(8682):170–171. [PubMed] [Google Scholar]
  47. Kanis J. A., Urwin G. H., Gray R. E., Beneton M. N., McCloskey E. V., Hamdy N. A., Murray S. A. Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med. 1987 Feb 23;82(2A):55–70. doi: 10.1016/0002-9343(87)90488-8. [DOI] [PubMed] [Google Scholar]
  48. Kemp B. E., Moseley J. M., Rodda C. P., Ebeling P. R., Wettenhall R. E., Stapleton D., Diefenbach-Jagger H., Ure F., Michelangeli V. P., Simmons H. A. Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science. 1987 Dec 11;238(4833):1568–1570. doi: 10.1126/science.3685995. [DOI] [PubMed] [Google Scholar]
  49. Kennedy B. J. Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med. 1970 Oct;49(4):494–503. doi: 10.1016/s0002-9343(70)80044-4. [DOI] [PubMed] [Google Scholar]
  50. Kiang D. T., Loken M. K., Kennedy B. J. Mechanism of the hypocalcemic effect of mithramycin. J Clin Endocrinol Metab. 1979 Feb;48(2):341–344. doi: 10.1210/jcem-48-2-341. [DOI] [PubMed] [Google Scholar]
  51. Leunissen K. M., Vismans F. J., van Leendert R. J., van Hooff J. P. Successful treatment of persistent posttransplant hyperparathyroidism with diphosphonate. Transplantation. 1986 May;41(5):666–667. [PubMed] [Google Scholar]
  52. Logue F. C., Beastall G. H., Fraser W. D., O'Reilly D. S. Intact parathyroid hormone assays. BMJ. 1990 Jan 27;300(6719):210–211. doi: 10.1136/bmj.300.6719.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. MYERS W. P. L. Cortisone in the treatment of hypercalcemia in neoplastic disease. Cancer. 1958 Jan-Feb;11(1):83–88. doi: 10.1002/1097-0142(195801/02)11:1<83::aid-cncr2820110117>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  54. Mawer E. B., Hann J. T., Berry J. L., Davies M. Vitamin D metabolism in patients intoxicated with ergocalciferol. Clin Sci (Lond) 1985 Feb;68(2):135–141. doi: 10.1042/cs0680135. [DOI] [PubMed] [Google Scholar]
  55. McIntyre H. D., Cameron D. P., Urquhart S. M., Davies W. E. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J. 1989 Apr;65(762):244–246. doi: 10.1136/pgmj.65.762.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Merlini G., Fitzpatrick L. A., Siris E. S., Bilezikian J. P., Birken S., Beychok S., Osserman E. F. A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. J Clin Immunol. 1984 May;4(3):185–196. doi: 10.1007/BF00914965. [DOI] [PubMed] [Google Scholar]
  57. Miach P. J., Dawborn J. K., Martin T. J., Moon W. J. Management of the hypercalcaemia of malignancy by peritoneal dialysis. Med J Aust. 1975 Jun 21;1(25):782–784. [PubMed] [Google Scholar]
  58. Morton A. R., Cantrill J. A., Craig A. E., Howell A., Davies M., Anderson D. C. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. Br Med J (Clin Res Ed) 1988 Mar 19;296(6625):811–814. doi: 10.1136/bmj.296.6625.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Mundy G. R., Martin T. J. The hypercalcemia of malignancy: pathogenesis and management. Metabolism. 1982 Dec;31(12):1247–1277. doi: 10.1016/0026-0495(82)90012-9. [DOI] [PubMed] [Google Scholar]
  60. Mundy G. R., Wilkinson R., Heath D. A. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med. 1983 Mar;74(3):421–432. doi: 10.1016/0002-9343(83)90961-0. [DOI] [PubMed] [Google Scholar]
  62. Paterson A. D., Kanis J. A., Cameron E. C., Douglas D. L., Beard D. J., Preston F. E., Russell R. G. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol. 1983 May;54(1):121–132. doi: 10.1111/j.1365-2141.1983.tb02074.x. [DOI] [PubMed] [Google Scholar]
  63. Patten B. M., Bilezikian J. P., Mallette L. E., Prince A., Engel W. K., Aurbach G. D. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med. 1974 Feb;80(2):182–193. doi: 10.7326/0003-4819-80-2-182. [DOI] [PubMed] [Google Scholar]
  64. Payne R. B., Carver M. E., Morgan D. B. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol. 1979 Jan;32(1):56–60. doi: 10.1136/jcp.32.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Peacock M., Robertson W. G., Nordin B. E. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969 Feb 22;1(7591):384–386. doi: 10.1016/s0140-6736(69)91353-1. [DOI] [PubMed] [Google Scholar]
  66. Percival R. C., Paterson A. D., Yates A. J., Beard D. J., Douglas D. L., Neal F. E., Russell R. G., Kanis J. A. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer. 1985 May;51(5):665–669. doi: 10.1038/bjc.1985.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Percival R. C., Yates A. J., Gray R. E., Neal F. E., Forrest A. R., Kanis J. A. Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) 1984 Aug 4;289(6440):287–287. doi: 10.1136/bmj.289.6440.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Perlia C. P., Gubisch N. J., Wolter J., Edelberg D., Dederick M. M., Taylor S. G., 3rd Mithramycin treatment of hypercalcemia. Cancer. 1970 Feb;25(2):389–394. doi: 10.1002/1097-0142(197002)25:2<389::aid-cncr2820250217>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  69. Ralston S. H., Alzaid A. A., Gallacher S. J., Gardner M. D., Cowan R. A., Boyle I. T. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med. 1988 Oct;68(258):825–834. [PubMed] [Google Scholar]
  70. Ralston S. H., Alzaid A. A., Gardner M. D., Boyle I. T. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Br Med J (Clin Res Ed) 1986 Jun 14;292(6535):1549–1550. doi: 10.1136/bmj.292.6535.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Ralston S. H., Fogelman I., Gardner M. D., Dryburgh F. J., Cowan R. A., Boyle I. T. Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium. Clin Sci (Lond) 1984 Feb;66(2):187–191. doi: 10.1042/cs0660187. [DOI] [PubMed] [Google Scholar]
  72. Ralston S. H., Gallacher S. J., Patel U., Campbell J., Boyle I. T. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990 Apr 1;112(7):499–504. doi: 10.7326/0003-4819-112-7-499. [DOI] [PubMed] [Google Scholar]
  73. Ralston S. H., Gallacher S. J., Patel U., Dryburgh F. J., Fraser W. D., Cowan R. A., Boyle I. T. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180–1182. doi: 10.1016/s0140-6736(89)91791-1. [DOI] [PubMed] [Google Scholar]
  74. Ralston S. H., Gallacher S. J., Patel U., Fraser W. D., Dryburgh F. J., Boyle I. T. Use of bisphosphonates in hypercalcaemia due to malignancy. Lancet. 1990 Mar 24;335(8691):737–737. doi: 10.1016/0140-6736(90)90859-4. [DOI] [PubMed] [Google Scholar]
  75. Ralston S. H., Gardner M. D., Dryburgh F. J., Jenkins A. S., Cowan R. A., Boyle I. T. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet. 1985 Oct 26;2(8461):907–910. doi: 10.1016/s0140-6736(85)90848-7. [DOI] [PubMed] [Google Scholar]
  76. Ralston S. H., Gardner M. D., Jenkins A. S., McKillop J. H., Boyle I. T. Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy. Bone Miner. 1987 May;2(3):227–242. [PubMed] [Google Scholar]
  77. Rastad J., Benson L., Johansson H., Knuutila M., Pettersson B., Wallfelt C., Akerström G., Ljunghall S. Clodronate treatment in patients with malignancy-associated hypercalcemia. Acta Med Scand. 1987;221(5):489–494. doi: 10.1111/j.0954-6820.1987.tb01285.x. [DOI] [PubMed] [Google Scholar]
  78. Ryzen E., Martodam R. R., Troxell M., Benson A., Paterson A., Shepard K., Hicks R. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med. 1985 Mar;145(3):449–452. [PubMed] [Google Scholar]
  79. SIMPSON J. A. Aphonia and deafness in hyperparathyroidism. Br Med J. 1954 Feb 27;1(4860):494–496. doi: 10.1136/bmj.1.4860.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]
  81. Shane E., Baquiran D. C., Bilezikian J. P. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med. 1981 Jul;95(1):23–27. doi: 10.7326/0003-4819-95-1-23. [DOI] [PubMed] [Google Scholar]
  82. Shane E., Jacobs T. P., Siris E. S., Steinberg S. F., Stoddart K., Canfield R. E., Bilezikian J. P. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate. Am J Med. 1982 Jun;72(6):939–944. doi: 10.1016/0002-9343(82)90855-5. [DOI] [PubMed] [Google Scholar]
  83. Silva O. L., Becker K. L. Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med. 1973 Sep;132(3):337–339. [PubMed] [Google Scholar]
  84. Singer F. R., Adams J. S. Abnormal calcium homeostasis in sarcoidosis. N Engl J Med. 1986 Sep 18;315(12):755–757. doi: 10.1056/NEJM198609183151209. [DOI] [PubMed] [Google Scholar]
  85. Singer F. R., Neer R. M., Murray T. M., Keutmann H. T., Deftos L. J., Potts J. T., Jr Mithramycin treatment of intractable hypercalcemia due to parathyroid carcinoma. N Engl J Med. 1970 Sep 17;283(12):634–636. doi: 10.1056/NEJM197009172831206. [DOI] [PubMed] [Google Scholar]
  86. Siris E. S., Hyman G. A., Canfield R. E. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med. 1983 Mar;74(3):401–406. doi: 10.1016/0002-9343(83)90958-0. [DOI] [PubMed] [Google Scholar]
  87. Siris E. S., Sherman W. H., Baquiran D. C., Schlatterer J. P., Osserman E. F., Canfield R. E. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med. 1980 Feb 7;302(6):310–315. doi: 10.1056/NEJM198002073020602. [DOI] [PubMed] [Google Scholar]
  88. Sleeboom H. P., Bijvoet O. L., van Oosterom A. T., Gleed J. H., O'Riordan J. L. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet. 1983 Jul 30;2(8344):239–243. doi: 10.1016/s0140-6736(83)90231-3. [DOI] [PubMed] [Google Scholar]
  89. Streeto J. M. Acute hypercalcemia simulating basilar-artery insufficiency. N Engl J Med. 1969 Feb 20;280(8):427–429. doi: 10.1056/NEJM196902202800807. [DOI] [PubMed] [Google Scholar]
  90. Suki W. N., Eknoyan G., Rector F. C., Jr, Seldin D. W. The renal diluting and concentrating mechanism in hypercalcemia. Nephron. 1969;6(1):50–61. doi: 10.1159/000179715. [DOI] [PubMed] [Google Scholar]
  91. Suki W. N., Yium J. J., Von Minden M., Saller-Hebert C., Eknoyan G., Martinez-Maldonado M. Acute treatment of hypercalcemia with furosemide. N Engl J Med. 1970 Oct 15;283(16):836–840. doi: 10.1056/NEJM197010152831603. [DOI] [PubMed] [Google Scholar]
  92. Tan T. T., Alzaid A. A., Sutcliffe N., Gardner M. D., Thomson J. A., Boyle I. T. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate. Postgrad Med J. 1988 Mar;64(749):224–227. doi: 10.1136/pgmj.64.749.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Tashjian A. H., Jr Editorial: Prostaglandins, hypercalcemia and cancer. N Engl J Med. 1975 Dec 18;293(25):1317–1318. doi: 10.1056/NEJM197512182932511. [DOI] [PubMed] [Google Scholar]
  94. Thalassinos N. C., Joplin G. F. Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet. 1970 Sep 12;2(7672):537–538. doi: 10.1016/s0140-6736(70)91345-0. [DOI] [PubMed] [Google Scholar]
  95. Thalassinos N., Joplin G. F. Phosphate treatment of hypercalcaemia due to carcinoma. Br Med J. 1968 Oct 5;4(5622):14–19. doi: 10.1136/bmj.4.5622.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Thiébaud D., Jaeger P., Jacquet A. F., Burckhardt P. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate. J Bone Miner Res. 1986 Dec;1(6):555–562. doi: 10.1002/jbmr.5650010610. [DOI] [PubMed] [Google Scholar]
  97. Thiébaud D., Portmann L., Jaeger P., Jacquet A. F., Burckhardt P. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy. Bone. 1986;7(4):247–253. doi: 10.1016/8756-3282(86)90203-6. [DOI] [PubMed] [Google Scholar]
  98. VERNER J. V., Jr, ENGEL F. L., McPHERSON H. T. Vitamin D intoxication: report of two cases treated with cortisone. Ann Intern Med. 1958 Apr;48(4):765–773. doi: 10.7326/0003-4819-48-4-765. [DOI] [PubMed] [Google Scholar]
  99. WARWICK O. H., YENDT E. R., OLIN J. S. The clinical features of hypercalcemia associated with malignant disease. Can Med Assoc J. 1961 Sep 23;85:719–723. [PMC free article] [PubMed] [Google Scholar]
  100. Warrell R. P., Jr, Bockman R. S., Coonley C. J., Isaacs M., Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest. 1984 May;73(5):1487–1490. doi: 10.1172/JCI111353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Warrell R. P., Jr, Coonley C. J., Straus D. J., Young C. W. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer. 1983 Jun 1;51(11):1982–1987. doi: 10.1002/1097-0142(19830601)51:11<1982::aid-cncr2820511104>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  102. Warrell R. P., Jr, Israel R., Frisone M., Snyder T., Gaynor J. J., Bockman R. S. Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med. 1988 May;108(5):669–674. doi: 10.7326/0003-4819-108-5-669. [DOI] [PubMed] [Google Scholar]
  103. Watson L., Moxham J., Fraser P. Hydrocortisone suppression test and discriminant analysis in differential diagnosis of hypercalcaemia. Lancet. 1980 Jun 21;1(8182):1320–1325. doi: 10.1016/s0140-6736(80)91784-5. [DOI] [PubMed] [Google Scholar]
  104. Weidmann P., Massry S. G., Coburn J. W., Maxwell M. H., Atleson J., Kleeman C. R. Blood pressure effects of acute hypercalcemia. Studies in patients with chronic renal failure. Ann Intern Med. 1972 May;76(5):741–745. doi: 10.7326/0003-4819-76-5-741. [DOI] [PubMed] [Google Scholar]
  105. Wisneski L. A., Croom W. P., Silva O. L., Becker K. L. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther. 1978 Aug;24(2):219–222. doi: 10.1002/cpt1978242219. [DOI] [PubMed] [Google Scholar]
  106. Witte R. S., Koeller J., Davis T. E., Benson A. B., 3rd, Durie B. G., Lipton A., Stock J. L., Citrin D. L., Jacobs T. P. Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med. 1987 May;147(5):937–939. doi: 10.1001/archinte.147.5.937. [DOI] [PubMed] [Google Scholar]
  107. Wynick D., Ratcliffe W. A., Heath D. A., Ball S., Barnard M., Bloom S. R. Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related protein. BMJ. 1990 May 19;300(6735):1314–1315. doi: 10.1136/bmj.300.6735.1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Yates A. J., Jones T. H., Mundy K. I., Hague R. V., Brown C. B., Guilland-Cumming D., Kanis J. A. Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) 1984 Oct 27;289(6452):1111–1112. doi: 10.1136/bmj.289.6452.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Yates A. J., Murray R. M., Jerums G. J., Martin T. J. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy. Aust N Z J Med. 1987 Aug;17(4):387–391. doi: 10.1111/j.1445-5994.1987.tb00070.x. [DOI] [PubMed] [Google Scholar]
  110. van Breukelen F. J., Bijvoet O. L., Frijlink W. B., Sleeboom H. P., Mulder H., van Oosterom A. T. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif Tissue Int. 1982 Jul;34(4):321–327. doi: 10.1007/BF02411261. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES